EGFR-IN-2

Catalog No.: 
ACDTDG332
CAS No.: 
1643497-70-4
Molecular Formula: 
C26H33N9O3S
Molecular Weight: 
551.68
EGFR-IN-2 structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1mg98%$306.00InquiryInquiry
5mg98%$756.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameEGFR-IN-2
IUPAC Name(S)-2-(1-(1-(sec-butyl)-6-((2-(1-(cyclopropylsulfonyl)-1H-pyrazol-4-yl)pyrimidin-4-yl)amino)-1H-pyrazolo[4,3-c]pyridin-3-yl)azetidin-3-yl)propan-2-ol
Molecular FormulaC26H33N9O3S
Molecular Weight551.68
SMILESOC(C)(C)C1CN(C2=NN([C@@H](C)CC)C3=C2C=NC(NC4=NC(C5=CN(S(=O)(C6CC6)=O)N=C5)=NC=C4)=C3)C1
InChI KeyRDWYRIOEHIKPRE-INIZCTEOSA-N
SynonymEGFR-IN-2;EGFRIN2,EGFR IN 2;3-Azetidinemethanol, 1-[6-[[2-[1-(cyclopropylsulfonyl)-1H-pyrazol-4-yl]-4-pyrimidinyl]amino]-1-[(1S)-1-methylpropyl]-1H-pyrazolo[4,3-c]pyridin-3-yl]-α,α-dimethyl-
CAS No.1643497-70-4

Synthetic Route by SureRoute

1. ACDTDG332 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACWTFO678 route compound structure diagram
    ACWTFO6781612172-62-9In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACDTDG332 route product structure diagram
    ACDTDG3321643497-70-4
Inquiry

2. ACDTDG332 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACAPKD623 route compound structure diagram
    ACAPKD6231357923-33-1In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACDTDG332 route product structure diagram
    ACDTDG3321643497-70-4
Inquiry

3. ACDTDG332 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACAPKD623 route compound structure diagram
    ACAPKD6231357923-33-1In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACDTDG332 route product structure diagram
    ACDTDG3321643497-70-4
Inquiry

Comments (0)